Table 2.
Subsequent PARP inhibitor or platinum therapy (ITT population)
| Talazoparib (N = 287) | Chemotherapy (N = 144) | |
|---|---|---|
|
| ||
| Received subsequent PARP inhibitor or platinum, n (%) | 139 (48.4) | 86 (59.7) |
| PARP inhibitor | 13 (4.5) | 47 (32.6) |
| Olaparib | 8 (2.8) | 36 (25.0) |
| PARP inhibitor | 3 (1.0)a | 8 (5.6) |
| Veliparib | 2 (0.7) | 5 (3.5) |
| Platinum | 133 (46.3) | 60 (41.7) |
| Carboplatin | 111 (38.7) | 49 (34.0) |
| Cisplatin | 29 (10.1) | 10 (6.9) |
| Oxaliplatin | 0 | 2 (1.4) |
a
Three patients who took commercial talazoparib after discontinuation of talazoparib in the study are shown in the PARP inhibitor class.
ITT, intent-to-treat; PARP, poly(ADP-ribose) polymerase.